Manel Cascalló
Corporate Officer/Principal bei THERIVA BIOLOGICS, INC.
Aktive Positionen von Manel Cascalló
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
THERIVA BIOLOGICS, INC. | Corporate Officer/Principal | 23.03.2022 | - |
Karriereverlauf von Manel Cascalló
Ehemalige bekannte Positionen von Manel Cascalló
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Vorstandsvorsitzender | - | - |
Vorsitzender | - | - |
Ausbildung von Manel Cascalló
University of Barcelona | Doctorate Degree |
Statistik
International
Spanien | 3 |
Vereinigte Staaten | 2 |
Operativ
Chief Executive Officer | 1 |
Chairman | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Commercial Services | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
THERIVA BIOLOGICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
- Börse
- Insiders
- Manel Cascalló
- Erfahrung